Megan Vigil, MD
Family Medicine · Ronan, MTNPI 1023450798
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 66 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 17 manufacturers, the largest accounting for just 23.7% — the pattern of someone who eats at a lot of different presentations.
Across 66 payments — averaging $15.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$247
- Lilly USA, LLC$132
- AstraZeneca$128
- AbbVie$113
- Exact Sciences$95
- Amgen$55
- plus $275 from 11 others
What the payments were for
- Food & beverage$1,045100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 16 | $247 |
| Lilly USA, LLC | 8 | $132 |
| AstraZeneca | 9 | $128 |
| AbbVie | 6 | $113 |
| Exact Sciences | 5 | $95 |
| Amgen | 3 | $55 |
| Sanofi Pasteur Inc. | 3 | $50 |
| Pfizer | 4 | $48 |
| Novo Nordisk | 3 | $43 |
| Vanda Pharmaceuticals Inc. | 2 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $13 |
| GSK | 1 | $13 |
| Organon | 1 | $12 |
| Radius Health, Inc. | 1 | $12 |
| Corium, LLC | 1 | $7 |
How this compares
$1,045 in reported general payments places this provider in the 85th percentile of 426 family medicine providers in Montana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 61 | $58,420 |
| EliquisApixaban | 129 | $57,717 |
| JardianceEmpagliflozin | 62 | $57,342 |
| TrulicityDulaglutide | 34 | $43,616 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $36,266 |
| RybelsusSemaglutide | 25 | $25,850 |
| FarxigaDapagliflozin Propanediol | 57 | $24,504 |
| XareltoRivaroxaban | 25 | $21,582 |
| CreonLipase/Protease/Amylase | 49 | $14,717 |
| JanuviaSitagliptin Phosphate | 42 | $13,717 |
| MounjaroTirzepatide | 12 | $13,124 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 17 | $10,952 |
| Repatha SureclickEvolocumab | 19 | $10,359 |
| Spiriva RespimatTiotropium Bromide | 15 | $9,132 |
| Oxcarbazepine | 51 | $8,264 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $43 | $84,27086 claims |
| PfizerEliquis | $48 | $57,717129 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $132 | $56,74046 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $13 | $47,21862 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Bevespi Aerosphere | $128 | $36,02879 claims |
| AbbVieCreon, Linzess, Savella | $113 | $27,789109 claims |
| MerckJanuvia, Dulera | $247 | $19,35058 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 426 family medicine providers in Montana.
Other family medicine in Ronan
- Laura HogansonRonan$1K
- Edred VizcarraRonan$894
- Daniel MoulletRonan$728
- Kimberly BlakesleeMissoula$186K
- Kathleen Harder-BrouwerHamilton$28K
- Joey BanksMissoula$21K
- Julie ReilBillings$9K
- Jeanne Pereles OrtizBillings$7K
- Aubrey RemmersMissoula$5K
- Lyle OnstadGreat Falls$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.